Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction

Area of Science:

• Neuroimmunology
• Pediatric Neurology
• Rare Diseases

Background:

• Langerhans cell histiocytosis with neurologic dysfunction (LCH-ND) presents significant challenges due to incomplete treatment responses.
• Rituximab has demonstrated clinical benefit in other neurodegenerative conditions, such as multiple sclerosis.

Purpose of the Study:

• To evaluate the efficacy and safety of rituximab as a novel treatment for patients diagnosed with LCH-ND.
• To explore rituximab's potential in addressing the complex neurological manifestations of LCH-ND.

Main Methods:

• Retrospective chart review of eight LCH-ND patients who had previously failed other therapies.
• Assessment of clinical signs/symptoms and magnetic resonance imaging (MRI) responses in patients treated with rituximab.

Main Results:

• Seven out of eight patients (87.5%) showed some degree of clinical improvement.
• Improvements were observed in motor functions (gait abnormalities, tremors) and sensory deficits (proprioception).
• Significant improvements in intellectual, behavioral, and psychological symptoms were noted in five patients (62.5%).

Conclusions:

• Rituximab appears to be a potentially effective therapeutic option for LCH-ND, offering clinical benefits.
• The findings support the need for prospective studies to definitively establish the safety and efficacy of rituximab in LCH-ND patients.